The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Avila Therapeutics

Biotech Trends Update — Commercialization by Foundations: Lymphoma and Leukaemia Society’s Preclinical Program Has Advantages for Companies

In my first post noting the trend of non-profit foundations stepping in to support commercial projects, I held out the  Leukemia & Lymphoma Society (LLS)’s Therapy Acceleration Program as a key example.

LLS recently made another investment from that program, giving $3.2 million to get Avila Therapeutics’ AVL-292 into trials for B-cell cancers (pdf).  In writing about this trend originally, I had emphasized the value for the recipeint companies of a non-dilutive investment in a difficult funding environment; but John Carroll’s article at FierceBiotech on the LLS-Avila deal notes another key advantage of these collaborations:

“The LLS offers a developer like Avila other strategic advantages, says [Avila’s CEO Katrine] Bosley. The society doesn’t just support patients, it also has ‘a network of relationships with clinical investigators.’ The LLS can help make introductions between the biotech and the investigators who can provide important insights on clinical trial protocols.”

The advantage for LLS? As Louis DeGennaro, Ph.D., LLS’s chief mission officer, says:

“Last year we had three partnerships, each of which triggered a clinical trial of an agent that would not have been tested in blood cancers if not for our dollars.”

A win-win situation that you can expect to see more of.

Follow

Get every new post delivered to your Inbox.

Join 131 other followers